Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

被引:0
|
作者
Almulhem, Maryam [1 ,2 ]
Ward, Christopher [1 ]
Haq, Iram [1 ,3 ]
Gray, Robert D. [4 ]
Brodlie, Malcolm [1 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[2] King Faisal Univ, Coll Appl Med Sci, Al Hasa, Saudi Arabia
[3] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Resp Med, Newcastle Upon Tyne, England
[4] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland
关键词
pulmonary exacerbation; cystic fibrosis; definition; QUALITY-OF-LIFE; CHILDREN; ADULTS; TRIAL; AZITHROMYCIN; RATIONALE; FREQUENCY; OUTCOMES; DESIGN; FEV1;
D O I
10.1136/bmjresp-2024-002456
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them.Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis.Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis.Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Self-management interventions for people with pulmonary fibrosis: a scoping review
    Lee, Joanna Y. T.
    Tikellis, Gabriella
    Dowman, Leona
    Jones, Arwel W.
    Hoffman, Mariana
    Mellerick, Christie R.
    Malaguti, Carla
    Khor, Yet H.
    Holland, Anne E.
    EUROPEAN RESPIRATORY REVIEW, 2023, 32 (170):
  • [22] Pulmonary Aspergillosis in People with Cystic Fibrosis
    Schwarz, C.
    Eschenhagen, P. N.
    Mainz, J. G.
    Schmidergall, T.
    Schuette, H.
    Romanowska, E.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (01) : 128 - 140
  • [23] Measuring the burden of cystic fibrosis: A scoping review
    Cheema, Zain M.
    Gomez, Lilian C.
    Johnson, Noah
    Laflamme, Olivier D.
    Rabin, Harvey R.
    Steele, Kim
    Wallenburg, John
    Leong, Jeanette
    Cheng, Stephanie Y.
    Quon, Bradley S.
    Stephenson, Anne L.
    Wranik, W. Dominika
    Sadatsafavi, Mohsen
    Stanojevic, Sanja
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (05) : 823 - 830
  • [24] USE OF DIFFERENT PULMONARY EXACERBATION DEFINITIONS IN THE PHASE 3 CLINICAL TRIAL OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS
    Konstan, M. W.
    Rowe, S. M.
    Accurso, F. J.
    Kerem, E.
    Wilschanski, M.
    De Boeck, K.
    Sermet-Gaudelus, I
    Miller, N. L.
    Elfring, G. L.
    Spiegel, R.
    Peltz, S.
    Barth, J.
    Ajayi, T.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 298 - 298
  • [25] Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
    Sawant, Akhil
    Spoletini, Giulia
    Whitaker, Paul
    Etherington, Christine
    Clifton, Ian
    Peckham, Daniel
    ERJ OPEN RESEARCH, 2018, 4 (01)
  • [26] What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis
    Abbott, J.
    Holt, A.
    Hart, A.
    Morton, A. M.
    MacDougall, L.
    Pogson, M.
    Milne, G.
    Rodgers, H. C.
    Conway, S. P.
    JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (05) : 356 - 359
  • [27] LONGITUDINAL MICROBIAL ECOLOGY IN CYSTIC FIBROSIS: IN AND OUT OF PULMONARY EXACERBATION
    Planet, P. J.
    Harasym, M.
    Quittell, L.
    Saiman, L.
    Prince, A.
    PEDIATRIC PULMONOLOGY, 2010, : 356 - 356
  • [28] ACUTE CORONARY SYNDROME PRESENTING AS A CYSTIC FIBROSIS PULMONARY EXACERBATION
    Olivero, Anthony
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U331 - U331
  • [29] Extracellular vesicles in the sputum of children with cystic fibrosis and pulmonary exacerbation
    Ben-Meir, Autoren E.
    Antounians, L.
    Ratjen, F.
    Zani, A.
    Grasemann, H.
    KLINISCHE PADIATRIE, 2022, 234 (05): : 341 - 341
  • [30] USE OF INHALED TOBRAMYCIN FOR TREATMENT OF CYSTIC FIBROSIS PULMONARY EXACERBATION
    Lubsch, L.
    Carlson, A.
    Albers, G.
    Armbrecht, E.
    PEDIATRIC PULMONOLOGY, 2011, : 349 - 349